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Anti-inﬂammatoryPhosphodiesterase-4B (PDE4B) regulates the pro-inﬂammatory Toll Receptor –Tumor Necrosis Factor α (TNFα)
pathway in monocytes, macrophages and microglial cells. As such, it is an important, although under-exploited
molecular target for anti-inﬂammatory drugs. This is due in part to the difﬁculty of developing selective PDE4B
inhibitors as the amino acid sequence of the PDE4 active site is identical in all PDE4 subtypes (PDE4A-D). We
show that highly selective PDE4B inhibitors can bedesignedby exploiting sequence differences outside the active
site. Speciﬁcally, PDE4B selectivity can be achieved by capture of a C-terminal regulatory helix, now termed CR3
(Control Region 3), across the active site in a conformation that closes access by cAMP. PDE4B selectivity is driven
by a single amino acid polymorphism in CR3 (Leu674 in PDE4B1 versus Gln594 in PDE4D). The reciprocal muta-
tions in PDE4B and PDE4D cause a 70–80 fold shift in selectivity. Our structural studies show that CR3 is ﬂexible
and can adoptmultiple orientations andmultiple registries in the closed conformation. The new co-crystal struc-
ture with bound ligand provides a guide map for the design of PDE4B selective anti-inﬂammatory drugs.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.1. Introduction
Studies of targeted PDE4 gene deletions in mice by Jin and Conti, as
well as others, have shown that the different PDE4 enzymes have
non-redundant functions [1–6]. PDE4 is encoded by four different
genes (PDE4A, PDE4B, PDE4C and PDE4D). These differ in their pat-
tern of expression in the body, and differ in their pattern of targeting
to subcellular compartments. The PDE4 family are the primary cAMP
hydrolyzing enzymes in cells, and as such, shape the spatial and tem-
poral patterning of cAMP signaling within cellular microdomains.
PDE4B is a well-validated target for modulating inﬂammation. For
example, tumor necrosis factor (TNF-α) production by macrophages
in response to an inﬂammatory stimulus is mediated by the Toll recep-
tor pathway through an increase in PDE4B gene expression [2,3]. The
increase in PDE4B drives down cAMP levels in themacrophage, thereby
causing an increase in TNFα production. PDE4B is the major PDE4 in
macrophages, and deletion of PDE4B in mice blunts the production of
TNFα in response to inﬂammatory stimuli. PDE4B selective inhibitors
similarly suppress TNF-α production in rodent models [7]. PDE4B
dysregulation may also be important in psychiatric disease [8].rand Rapids, MI, USA.
ey).
. Open access under CC BY-NC-SA licEach PDE4 gene encodesmultiple transcripts that produce three iso-
forms of the enzyme termed long, short and super short. Long isoforms
of PDE4 contain two upstream control regions known as UCR1 and
UCR2 (upstream conserved region 1 and 2). These form a negative regu-
latory module which is relieved by protein kinase A (PKA) phosphoryla-
tion of UCR1 in response to cAMP (Fig. 1A) [9]. Burgin et al. demonstrated
that this negative regulation resulted from a control helix within the
UCR2 domain that can close over the active site [10]. The “closed” UCR2
conformation was visualized by X-ray crystallography using small mole-
cules that bound in the active site and simultaneously interacted with
speciﬁc residues in UCR2, most importantly Phe196. This residue is not
conserved among PDE4 genes. Instead, it is replaced by a tyrosine in
PDE4A-C. This has allowed the discovery of a number of PDE4D selective
inhibitors which exploit the UCR2 binding pose (e.g. RS25344, PMNPQ,
and D159153).
In the absence of UCR2,we showed previously that PMNPQ captures
a second, downstream C-terminal helix, now termed CR3 (Conserved
Region 3). CR3 is present in the protein constructs used to crystallize
the catalytic domain of PDE4 but is typically disorderedwithin the crys-
tal lattice presumably because the helix only weakly interacts with the
catalytic domain by itself. CR3 is visible in a number of PDE4 catalytic
domain structures (1F0J, 3HMV, 3W5E and 3KKT); however, the length
of CR3 that is visible is variable as is the orientation of CR3 in the
structure [11–13].
To better understand the role of CR3 in regulating PDE4 activity, we
surveyed additional compounds that could bind and stabilize CR3 over
the active site. We report here the analysis and X-ray crystal structureense.
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Fig. 1. PDE4B selective inhibitor captures the C-terminal CR3 bynovel bindingmode. A.Domain architecture for full-length PDE4 and the crystallization construct (PDE4BCAT + CR3).
B–D. A-33 (cyan) interaction with catalytic domain (blue) and CR3 (yellow). B. “P-clamp” and “Q-switch.” C. Hydrogen bonding network bridging CR3 and A-33 carboxylic acid.
D. Hydrophobic interactions with A-33 thiophene. Atom coloring — Oxygen (red), Nitrogen (blue), Carbon (cyan), Chloride (green), and Sulfur (yellow). Metals are shown as
large spheres (Mg2+ - green and Zn2+ - silver) and waters are shown as small red spheres. Hydrogen-bonds are represented by black dashed lines. PDB: 4MYQ.
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33, herein referred to a A-33) bound to PDE4B. Comparison of this struc-
ture with the PMNPQ-PDE4D (PDB: 3G58), NVW-PDE4B (PDB: 3W5E),
and OCP-PDE4B (PDB: 3KKT) structures, shows that small molecules
can interactwith different residues along the CR3 helix resulting inmul-
tiple “closed” conformations. The CR3 helix can adopt slightly different
orientations across the active site, each with unique helical registries;
however, only in the conformation observed in the new A-33 structure
do the sequence differences between the PDE4B and PDE4D enzymes
become critical for this interaction. In support of this model, we show
that the reciprocal exchange of a single amino acid residue in CR3
between the PDE4B and 4D long isoforms can convert the selectivity
proﬁle of A-33 for PDE4B into that of PDE4D, and vice versa. These
results demonstrate that CR3 can regulate PDE4 activity in biologically
relevant PDE4 isoforms, and enable the ﬁrst structure based drug design
program of PDE4B selective inhibitors.
2. Materials and methods
2.1. PDE4 protein constructs
PDE4D residue numbering is based on the reference PDE4D3 iso-
form, GenBank accession No. AAA97892, and PDE4B residue numbering
is on the reference PDE4B3, GenBank accession No. Q07343. Methods
used to generate synthetic genes for human PDE4B1 (Swiss-Prot:
Q07343.1) and PDE4D7 (GenBank: AAN10118.1) constructs are as
described in Burgin et al. [10]. Mutations in the PDE4B1 (L674Q) and
PDE4D7 (Q594L) constructs were cloned by site-directed mutagenesis
of the respective long-form construct. A synthetic gene encoding the
PDE4B catalytic domain and CR3 element (PDE4B-CR3, residues
324–691) with amino-terminal thrombin cleavable hexahistidine tag
was engineered for Baculovirus-infected insect cell expression using
Gene Composer™ software (Emerald Bio, Bainbridge Island, WA) [14].
The 389 amino acid fragment was cloned into a BV transfer vector, ex-
pression from which is driven by the polh promoter, using 5′ BamHI
and 3′ HindIII.
2.2. Expression and puriﬁcation of PDE4 proteins
PDE4 constructs were transfected into Sf9 insect cells (Expression
Systems) using BestBac 2.0, v-cath/chiA Deleted Linearized BaculovirusDNA (Expression Systems). Virus from each transfection was ampliﬁed
through 4 rounds to produce virus stock for large scale production. The
large scale preparations were grown in ESF921 medium (Expression
Systems) of approximately 2.5e6 cells per ml that was infected with
10% ﬁnal virus (75 ml) and harvested 48 h post-infection. Cells were
centrifuged to collect cell paste which was frozen drop-wise into liquid
nitrogen and stored at−80 °C.
Frozen cell paste of the PDE4 long form and catalytic domain proteins
was resuspended and lysed hypotonically in 20 mM tris(hydroxymethyl)
aminomethane (Tris) pH 8.0 containing one complete protease inhibitor
tablet for one hour at 4 °C. The lysate was clariﬁed by centrifugation at
42 K rpm for 45 min at 4 °C. Sodium chloride (NaCl) was added to the
clariﬁed lysate to obtain a ﬁnal concentration of 0.5 M. Clariﬁed lysate
was ﬁrst puriﬁed by immobilized metal afﬁnity chromatography with a
HiTrap™ Chelating HP column and an AKTA FPLC system. The protein
was eluted over a gradient with 20 mM Tris pH 8.0, 0.5 M NaCl and
0.5 M imidazole and the eluted fractions were analyzed via SDS-PAGE
prior to pooling. Long-form PDE4 proteins were dialyzed into the ﬁnal
buffer containing 20 mM TRIS at pH 8.0, 0.1 M NaCl, 0.1 mM MgCl2,
0.1 mM ZnCl2, and 2 mM dithiothreitol (DTT) and then ﬂash frozen
with liquid nitrogen in aliquots of 0.5 mL at 0.1 mg/ml as measured by
A280. The PDE4B-CR3 protein eluted poolwas further treatedwith throm-
bin to cleave the 6X His tag followed by removal of thrombin and the
cleaved fusion tag by passing the cleaved pool over a benzamidine col-
umn and a HiTrap™ Chelating HP column in series. Cleaved PDE4B-CR3
was collected in the ﬂow-through and dialyzed into the ﬁnal buffer
containing 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES) pH 7.5, 100 mM NaCl and 1 mM DTT. Cleaved PDE4B-
CR3 was concentrated via centrifugal concentration to a ﬁnal con-
centration of 7.9 mg/ml as measured by A280. All proteins were stored
at−80 °C.
2.3. Co-crystallization of PDE4B with A-33
Crystals of PDE4B-CR3were grown by sitting drop vapor diffusion at
295 K using 0.5 μl of 7.9 mg/ml protein in the presence of 0.5 mMA-33
(DMSO) and combined with 0.5 μl of crystallization buffer containing
328.6 mMpotassium formate, 24%w/v PEG3,350 (based on JCSG+ con-
dition A10) [15]. Crystals grown for data collection were streak seeded
using crystals described above and were cryo-protected using 20%
ethylene glycol mixed with 0.1 mM A-33.
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A 1.90 Ǻ dataset of a co-crystal of human PDE4B-CR3 and compound
A-33 was collected in-house at Emerald BioStructures on a Rigaku
SuperBright FR-E + X-ray generator with Osmic VariMax HF optics
and a Saturn 944+ CCD detector. Diffraction data were reduced and
scaled with XDS/XSCALE [16]. The structure of PDE4B-CR3 bound to
A-33 was solved by molecular replacement using pre-existing struc-
tures of the PDE4B catalytic domain (PDB: 3G45) [10]. The structure
was reﬁned using iterative cycles of TLS and restrained reﬁnement
with REFMAC5 [17], part of the CCP4 program suite [18], and model-
building using the Crystallographic Object-Oriented Toolkit (COOT)
[19]. The structure was peer-reviewed internally and validated using
Molprobity [20] prior to deposition in the Protein Data Bank (PDB:
4MYQ) [21,22]. Diffraction data and reﬁnement statistics are listed in
Table 1.
2.5. Kinetic assay of PDE4 activity.
Kinetic assay of cAMP hydrolysis by puriﬁed PDE4 is measured by
coupling the formation of the PDE4 reaction product, 5′-adenosine
monophosphate to the oxidation of reduced nicotinamide adenine
dinucleotide (NADH) by the use of three coupling enzymes (yeast
myokinase, pyruvate kinase and lactate dehydrogenase), which allows
ﬂuorescent determination of reaction rates [10]. Assays are performed
in 96-well plates in a total volume of 200 μl/well. Compounds are dis-
solved in dimethylsulfoxide (DMSO) and added to plates in a volume
of 10 μl followed by addition of 165 μl of assay mix. Plates are pre-
incubated at 25 °C for 15 min and the reactions are initiated by the
addition of 25 μl of cAMP followed by thorough mixing. Reaction ratesTable 1
Diffraction data and reﬁnement statistics.
PDB ID 4MYQ
Parameter Overall (Highest shell)
Protein VCID 6271 (PDE4B-CR3)
Ligand A-33
Beamline Rotating anode
Data collection
Collection date 16-Mar-2012
Space group P42
Unit cell a = b = 99.7 Å, c = 47.0 Å
α = β = γ = 90°
# molecules/asymmetric unit 1
Wavelength 1.5418
Solvent content 55.6%
Vm 2.7 Å3/Da
Resolution 50.0-1.90 Å (1.95-1.90)
I/σI 12.50 (2.29)
Completeness 97.3% (86.7%)
Rmerge 0.087 (0.483)
Multiplicity 3.30 (1.50)
Unique 35,759 (2,326)
Mosaicity 0.30
Reﬁnement statistics
Reﬂections 35,749 (2,117)
No. of non-hydrogen atoms 3,223
Resolution 49.85-1.90 Å (1.95-1.90)
Rcryst 0.190 (0.365)
Rfree 0.222 (0.401)
FreeR # of reﬂections 5%, 1,788 (117)
Average B-factor (Å2) 12.80
Model geometry
Bond length deviation (Å) 0.014
Bond angle deviation (°) 1.487
Ramachandran
Favored 98.53%
Allowed 100.0%
Molprobity score 99th percentileare measured by monitoring the decrease in ﬂuorescence using excita-
tion at 355 nm and emission at 460 nm for a period of 10 min in a
ﬂuorescence plate reader. Initial rates (slopes) are determined from
linear portions of the progress curves. Final concentrations of assay
components are as follows: 50 mM Tris, pH 8, 10 mM MgCl2, 50 mM
KCl, 2% DMSO, 5 mM tris(2-carboxyethyl)phosphine (TCEP), 0.4 mM
phosphenolpyruvate (PEP), 0.01 mM NADH, 0.04 mM adenosine tri-
phosphate (ATP), 0.004 mM cAMP, 7.5 units myokinase from yeast,
1.6 units pyruvate kinase, 2 units lactate dehydrogenase, and ~10 nM
PDE4. The concentration of puriﬁed PDE4 in the assay was adjusted to
yield an initial rate of approximately−0.7 RFU/s. All data are percent
normalized relative to controls and are presented as percent inhibition.
An inhibitory concentration 50% (IC50) value is calculated by ﬁtting a
sigmoidal dose response curve. Z′ quality factors are N0.6 for the
assay. Human PDE4D7 contained a mutation of S54D to mimic activa-
tion by cAMP-dependent protein kinase A (PKA) and S579A/S581A to
remove the potential for ERK-dependent phosphorylation. Human
PDE4B1 also contained the corresponding mutations S133D (PKA) and
S659A/S661A (ERK).
3. Results
Naganuma et al. discovered a series of arylpyrimidine PDE4 inhibi-
tors (e.g. A-33) with N100X selectivity for PDE4B versus PDE4D [7].
We showed separately that the observed afﬁnity and selectivity were
dependent on the presence of sequences C-terminal to the catalytic do-
main, which we now term “control region 3” (CR3) [23]. To understand
the structural basis of this selectivity, we attempted co-crystallization
trials with PDE4B catalytic domain constructs containing CR3, but lack-
ing UCR2, and obtained crystals that diffracted X-rays to 1.9 Å resolu-
tion (Fig. 1A). The resulting structure shows that A-33 makes multiple
interactions with the catalytic domain and simultaneously with resi-
dues from CR3 (Fig. 1B). A-33 binds the PDE4B catalytic domain with
its central pyrimidine ring stacked between Phe618 and Ile582 and in
position to hydrogen bond to Gln615. These constitute the “P clamp”
and “Q switch” interactions observed among all PDE4 inhibitors as
described by Card et al. [24]. The amine linker between the central
core and the arylcarboxymethyl group also makes a hydrogen bond to
a conserved water molecule constituting part of the hydration shell of
the catalytic metals. Finally, the ethyl and methyl substituents off of
the central pyrimidine ring provide shape complementarity to the Q1
hydrophobic pocket in the back of the active site. This model explains
why substituents at all of these positions are critical for potency but
have little effect on PDE4B vs. PDE4D selectivity [24], since the same
pockets are conserved in both active sites.
Naganuma et al. previously showed that the primary substituents
responsible for PDE4B selectivity are the thienyl and arylcarboxymethyl
substituents [7]. Our X-ray crystal structure shows that these groups
speciﬁcally interact with residues from CR3. The chloro-substituted
thienyl group of A-33 ﬁlls the Q2 pocket (Fig. 1D) at the interface be-
tween the catalytic domain (Met603, Phe618, and the backbone
Ser614) and CR3 (Lys677, Phe678 and Leu674). The carboxylic acid
moiety makes a water-mediated hydrogen bond contact to the main-
chain carbonyl of Lys677 (Fig. 1C), and the acid group makes a second
water-mediated hydrogen bond to the amine of Lys677, although the
distances are slightly longer than expected for an ideal interaction.
The amine of Lys677 directly ties CR3 to the catalytic domain through
a second hydrogen bond to the main-chain carbonyl of Pro602 on the
catalytic domain. Even weak interactions that would help position and
stabilize this Lys677-Pro602 interaction would be expected to have a
signiﬁcant effect on the overall binding energy of the closed complex
(A-33/catalytic domain/CR3). Together, these results show that A-33
has good shape complementarity as an interface between the catalytic
domain and CR3 and makes multiple hydrophobic and polar interac-
tions with both domains. This holds CR3 in a “closed conformation”
that blocks substrate binding.
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bind in the active site and engage CR3 (Fig. 2). For example, Burgin et al.
demonstrated that PMNPQ can bind the catalytic domain of PDE4D and
interact with CR3. The PMNPQ–CR3 interaction is only observed when
UCR2 is absent, which does not occur in any biological isoform of
PDE4. Otherwise, PMNPQ preferentially captures UCR2 and holds it
across the active site. In a second example, Goto et al. co-crystallized
a pyrimidine sulfone (NVW) bound to the PDE4B catalytic domain
which engages CR3 (PDB: 3W5E). This compound has a very similar
binding mode as the pyrimidinone, CP-80633 (OCP) [25], which also
co-crystallizes with CR3 of PDE4B (PDB: 3KKT, unpublished).
Comparison of the A-33 structure (PDB: 4MYQ) with the published
PMNPQ (PDB: 3G58), NVW (PDB: 3W5E), and OCP (PDB: 3KKT) crystal
structures shows that the CR3 helices have different orientations over
the active site (Fig. 2). The Cα carbons of CR3 from NVW (orange) and
OCP (green) are nearly superimposable but distinctly different in
orientation from the CR3 backbones in the A-33 (yellow) or PMNPQ
(magenta) structures. In addition, although the A-33 and PMNPQ CR3
helices are nearly superimposable, these helices are rotated relative to
one another by a single helical turn. Altogether, this results in three
different helical poses (Fig. 3B, C and D). As a result, the three different
helical poses present different amino acid residues and, therefore, dif-
ferent shapes and functional groups to the active site. The different
poses are presumably selected by chemical differences between the
inhibitors, and we hypothesize that the A-33 registry places amino
acid differences between PDE4B vs. PDE4D into a context that can affect
selectivity.
The PDE4D-CR3 helical register as captured by PMNPQ places
Phe598 toward the ligand interface at the same relative position as
Leu674 in the A-33 structure. It also points Lys597 (homologous to
PDE4B Lys677) away from the binding interface and prevents the criti-
cal water-mediated hydrogen bond interaction observed with A-33. If
the CR3 α-helix of PDE4D is placed in the PDE4B A-33 register, with
PDE4D Lys597 occupying the same relative position as PDE4B Lys677,
then PDE4D Gln594 faces the binding interface and Phe598 sterically
clashes with the chloro group from the thienyl moiety of A-33 (Fig. 4A).
Likewise, the PDE4D catalytic domain with PMNPQ bound, when
modeled with CR3 from PDE4B, suggests that the nitro group from the
phenyl moiety of PMNPQ would sterically clash with Leu674 of CR3
from PDE4B (not shown).CC
C
A B
Fig. 2. PDE4 inhibitors capture unique CR3 poses over the catalytic domain. A. PDE4B catalyt
CR3 helix (yellow-ribbon) and overlaid with the PMNPQ captured CR3 helix (magenta-ribbon)
(orange-ribbon) and overlaidwith the OCP captured CR3 helix (green-ribbon). C. Comparison o
domain and CR3 helices are indicated. Small molecules are removed from the ﬁgure for simplic
Lys677 (PDE4B)/Lys597 (PDE4D) are shown as sticks to illustrate relative CR3 helical registryComparison of the A-33 structure with the NVW and OCP-bound
structures shows that a two-residue shift in the helical registry brings
Leu674, Met675, and Phe678 to the interface with the ligand (NVW
and OCP) in the active site instead of Leu674, Lys677 and Phe678
(A-33). An overlay of the PDE4B catalytic domains shows that the chloro
substitution on the A-33 thienyl ring sterically clashes with Phe678 if
CR3 adopts the alternative pose (Fig. 4B and C). In addition, NVW and
OCP do not have moieties that can interact and stabilize the CR3 pose
observed in the A-33 structure. Together, these results show that each
CR3 pose is stabilized by unique interactions with ligands bound in
the active site, and speciﬁc interactions are predicted to destabilize
alternative poses. These results emphasize that the CR3 helix is very
ﬂexible. It is possible that additional small molecules could stabilize
alternative CR3 poses.
If the X-ray crystal structure reﬂects binding in a biological isoform,
it should explain why A-33 is N100× selective for PDE4B vs. PDE4D.
There are several non-conserved residues between PDE4D and PDE4B
within CR3 that could contribute to selectivity (highlighted in red in
Fig. 3A); however, there are only two residues (PDE4B Leu674/PDE4D
Gln594 and PDE4B Met675/PDE4D Thr595) that are in position to en-
gage the ligand and/or catalytic domain. In the model, Leu674 interacts
with the wall of the catalytic domain and with the thienyl group on
A-33. This provides a uniquely closed hydrophobic environment for
the compound, whichwe hypothesize, contributes to PDE4B selectivity.
Met675 is adjacent to the face of the catalytic domain; however, a thre-
onine at this position would not be expected to be detrimental to the
overall CR3 pose. If the glutamine vs. leucine difference is the basis for
selectivity, mutation of Gln594 → Leu (Q594L) in PDE4D should in-
crease A-33 potency, and conversely, the mutation Leu674 → Gln
(L674Q) in PDE4B should decrease A-33 potency. To test this hypothe-
sis, we placed these mutations in the physiological context of the long
splice isoforms, PDE4D7 and PDE4B1, which contain both N-terminal
regulatory domains (UCR1, with PKA phosphomimetic mutation
S → D [10], & UCR2) and CR3. Indeed, the single amino acid change
shifts A-33 IC50 from 1569 nM against PDE4D7 (wild-type CR3) to
21 nM against PDE4D7 Q594L (Fig. 5A). The reciprocal mutation in
PDE4B1 shifts A-33 IC50 from 32 nM against PDE4B1 (wild-type CR3)
to 2035 nM against PDE4B1 L674Q. These results indicate that the
large degree of PDE4B selectivity is due to this single amino acid differ-
ence between PDE4B and PDE4D.C
CC
C
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ic domain is shown as a surface representation (cyan, PDB: 4MYQ)with the A-33 captured
from PDE4D. B. PDE4B catalytic domain (PDB: 3W5E) with the NVW captured CR3 helix
f CR3 poses from the A-33, PMNPQ, NVWand OCP, colored as in A–B. C-termini of catalytic
ity, but the catalytic metals are highlighted in the active site (Mg2+ - green, Zn2+ - silver).
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Fig. 3. PDE4B inhibitor A-33 selects a speciﬁc CR3 pose. A. Sequence alignment of CR3. Top two lines show the long-form sequences for PDE4D (669–683) and PDE4B (589–603); non-
conserved amino acids are highlighted in red. Amino acid residues that can bemodeled in the A-33, PMNPQ, NVWand OCP structures are shown (colored as in Fig. 2). B–D.Helical wheel
representations are shown for the CR3 helices captured by (B) A-33, (C) PMNPQ, and (D)NVW/OCP. Helical wheel residue coloring: compound interface (red), catalytic domain interface
(green), and solvent interface (blue).
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We have obtained a 1.9 Å resolution crystal structure of A-33 [7]
bound in the active site of PDE4B while simultaneously stabilizing a
C-terminal α-helix across the active site (now termed Control Region
3, “CR3”), thereby locking the enzyme in an inactive “closed” conforma-
tion. This result mirrors N-terminal UCR2 structures that have been
exploited to develop PDE4D-selective allosteric modulators [10].
These preferentially interact with a non-conserved phenylalanine
residue (tyrosine in PDE4B). The PDE4B-selective inhibitor A-33
displays the typical P-clamp and Q-switch interactions previously de-
scribed for all PDE4 active site inhibitors [24]; however, A-33 also con-
tains a carboxylic acid moiety which reaches out of the active site and
engages CR3 through water mediated contacts. In addition, a chloro-
substituted thienyl group provides excellent shape complementarity
with a pocket formed between CR3 and the catalytic domain further
stabilizing the CR3 helix over the active site. Comparison of the A-33
structure with other PDE4 structures, in which CR3 is visible, that is,
when CR3 is stabilized by a small molecule ligand, clearly shows thatA
A-33
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Fig. 4. Modeling of other CR3 registries shows de-selection by A-33. A. A-33 overlaid with th
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tries. Each small molecule presents different chemical features that sta-
bilize different poses of CR3. Most importantly, A-33 stabilizes a unique
pose of CR3 over the active site that results in a non-conserved residue
(Leu674) interacting with both A-33 and the face of the catalytic
domain. Mutagenesis studies show that this CR3 pose is destabilized
in the PDE4D background resulting in PDE4B-selectivity.
Together, these results show that it is possible to generate highly
selective PDE4B inhibitors by exploiting sequence differences outside
of the catalytic domain. Although not yet described, it is possible that
small molecules could be developed that preferentially interact with
the non-conserved tyrosine in UCR2 to generate PDE4B-selective inhib-
itors. Similarly, because of the high degree of ﬂexibility of CR3, it is
possible that small molecules could be developed that preferentially
stabilize a CR3 conformation that would be unique to PDE4D. Despite
the fact that the active sites of all PDE4 enzymes are completely con-
served, there existmultiple structure-based design approaches to create
highly speciﬁc inhibitors by exploiting non-conserved residues within
the UCR2 and CR3 regulatory domains.678
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clash (red lines) with G617 of the catalytic domain, and 2) placement of a hydrophilic residue in a hydrophobic environment (lightning bolt). Coloring is as shown in Fig. 1. B. A-33
biochemical inhibition curves by PDE kinetic assay against PDE4D7, with wild-type CR3 (red, solid), PDE4D7 Q594L (red, dashed), PDE4B1, with wild-type CR3 (blue, solid), and
PDE4B1 L674Q (blue, dashed).
662 D. Fox 3rd et al. / Cellular Signalling 26 (2014) 657–663The physiological importance of the regulation of PDE4D activity by
UCR2 is underscored by human genetic data. Human PDE4D mutations
have been described in children with acrodysostosis, a developmental
disorder that causes mental retardation, short ﬁngers and toes, and
facial dysmorphia [26–28]. Acrodysostosis mutations map to UCR1,
UCR2 and catalytic domain residues that interact with UCR2. Thus, the
acrodysostosismutations are proposed to activate PDE4Dbydestabilizing
closure of UCR2 across the active site. Similar genetic support for the
physiological role of CR3 in the regulation of PDE4D or PDE4B activity
is not available. The CR3 helix may be important for RACK-1 binding
(receptors for activated C-kinase); however, there is no change in Km
or Vmax by RACK1-bound PDE4D5, so CR3 must be held in an open con-
formation [29,30]. It is also important to note that several other partner
proteins including AKAP18 [31], ERK2 [32] and beta-arrestin [29,30]
have been shown to bind a conserved “FQF” (Phe678-Gln679-Phe680)
motif present on CR3. Analysis of the A-33 structure shows that these
residues are not accessible in the closed conformation suggesting that
these partner proteins would stabilize a CR3 open conformation.
Additional experiments are needed to know if ligand binding would
minimize partner protein interactions, or if the presence of partner
proteins would mitigate ligand binding; however, it is interesting
to speculate that in addition to being gene selective, ligands with
bindingmodes similar to A-33would provide another level of speciﬁcity
by only engaging a speciﬁc subset of PDE4B-partner protein complexes
in vivo.
The ability to use structures to guide the design of PDE4B-selective
compounds acting through CR3 has very important implications for
developing PDE4 therapeutics. Vomiting and emesis were suggested
by Robichaud et al. to be associated with inhibition of PDE4D [33]. The
association of PDE4D inhibitionwith emesiswas corroborated by subse-
quent studies showing that selective PDE4D inhibitors are potent
emetogens in multiple species [10,34]. Thus, it has been hypothesized
that selective compounds targeting PDE4 isoforms other than PDE4D
will have reduced emetic potential. Naganuma et al. report that A-33
has a very favorable ratio of anti-inﬂammatory activity in mice and
high tolerability with respect to emesis in ferrets [7]. The structural re-
sults reported herein will facilitate the chemical optimization of small
molecule PDE4B inhibitors for treating inﬂammatory and psychiatric
diseases with reduced PDE4 family cross-reactivity.
5. Conclusions
Our structural and biochemical studies support inhibition of PDE4B
activity by novel interactions between catalytic domain bound aryl-
pyrimidine inhibitors and a C-terminal regulatory element known as
CR3.Sequence differences between the PDE4B and PDE4D CR3 domains
allow for selective inhibition of PDE4B by small molecules that favor
this new CR3 binding pose.
These data highlight the importance of engagingCR3 in a speciﬁc he-
lical register to achieve PDE4B selectivity and will enable the structure-
based design of PDE4B selective drugs for the treatment of inﬂammatory
and psychiatric diseases.
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